骨肿瘤细胞特异性结合肽修饰固体脂质纳米粒的肿瘤靶向性研究

Study on osteosarcoma targeting of solid lipid nanoparticles modified with peptides specifically binding to human osteosarcoma cells

目的制备骨肿瘤细胞特异性结合肽—SLT肽修饰的固体脂质纳米粒(SLT peptide modified solid lipid nanoparticles,SLT-SLNs),研究其与人骨肉瘤MG63细胞的亲和力和肿瘤靶向性。方法细胞摄取实验研究肿瘤细胞对SLT-SLNs的摄取。构建骨肿瘤裸鼠异位模型,研究不同固体脂质纳米粒的体内靶向性。结果 SLT-SLNs的平均粒径为(115.7±8.7)nm,多分散性系数为0.12,Zeta电位为(13±2.25)mV。细胞摄取实验结果显示MG63细胞对SLT-SLNs的摄取效率是SLNs的4.4倍(P<0.01);体内活体成像实验结果显示SLT-SLNs组荷瘤裸鼠肿瘤组织的荧光强度明显强于SLNs组。结论 SLT肽修饰的固体脂质纳米粒具有良好的骨肉瘤细胞亲和力,是一种潜在的高效骨肿瘤靶向给药系统。

Objective To prepare SLT peptide modified solid lipid nanoparticles(SLT-SLNs),study on its affinity to MG63 cell and tumor targeting.Methods Cellular uptake test was used to evaluate the uptake efficiency of MG63 cell for SLT-SLNs.MG63 cell were xenografted into athymic nude mice to establish the animal model,vivo imaging was used to evaluate the targeting efficiency. Results The average particle size of SLT-SLNs was (115.7 ±8.7)nm,polydispersity coefficient was 0.12,and Zeta potential was(13 ±2.25)mV.Cellular uptake test results showed that uptaken efficiency of SLT modified SLNs by MG63 cell were 4.4 times higher than that of SLNs.The fluorescence intensity of SLT-SLNs was much stronger than that of SLNs in vivo.Conclusion The SLT peptide modified solid lipid nanoparticles has a good osteosarcoma targeting efficiency,and it might serve as a promising osteosarcoma delivery system of antitumor drugs.